We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells Life Sciences Summit 2017

Wednesday, 29 November 2017
16:00 pm - 18:30 pm
London

Innovation, change and challenge: the evolving landscape in the Life Sciences sector.

We are excited to announce this year’s Hogan Lovells Life Sciences Summit hosted by our London Life Sciences team. Join us for a series of short talks to keep ahead of the developments that will impact your business. The sessions will include:


George Goldsmith, co-founder and director of COMPASS Pathways. COMPASS Pathways is an organisation dedicated to accelerating access to evidence-led innovation in mental health and wellbeing. Hear about COMPASS's current work in relation to the re-purposing and development of psilocybin, the psychoactive component of "magic" mushrooms, to help patients with treatment-resistant depression.


Blockchain and Life Sciences: maximising its potential.


Bridging the gap between creation and commercialisation: Biotechs want an exit route for their molecules. Pharma wants innovative treatments and reliable partners. Explore how best to collaborate and bridge the gap between creation and commercialisation.


Are your agreements up to date? A practical session focusing on what to add, change or think about in your contracts as a result of recent developments, including the latest on "endeavours" clauses, Brexit-proofing and more.


Life Sciences disputes: could the latest CJEU decisions bring new threats for your business?


The Brexit clock is ticking: what should Life Sciences companies be doing today?


International arbitration: with Life Sciences providing a growth injection for international arbitration, what do you need to be thinking about?


The Summit will last for around two hours and will be followed by networking drinks.


Click here to register your interest.

From Hogan Lovells

Loading data